Thompson, Meghan C.

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. (., et al. (2024) · Science

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 175

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

Seymour, J. F., Cheah, C. Y., Parrondo, R., Thompson, M. C., Stevens, D. A., Lasica, M., Wang, M. L., Kumar, A., Trotman, J., Alwan, M., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 71